2. Search Result
Search Result
Results for "

calcium levels

" in MedChemExpress (MCE) Product Catalog:

147

Inhibitors & Agonists

6

Fluorescent Dyes

9

Biochemical Assay Reagents

15

Peptides

20

Natural
Products

13

Isotope-Labeled Compounds

1

Click Chemistry

3

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17504
    Rosuvastatin Calcium
    20+ Cited Publications

    Rosuvastatin hemicalcium; ZD 4522 calcium

    		 HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Calcium
  • HY-P2273
    Calcitonin (human)

    		CGRP Receptor Metabolic Disease
    Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .
    Calcitonin (human)
  • HY-112490
    Atorvastatin calcium hydrate
    Maximum Cited Publications
    65 Publications Verification

    		 HMG-CoA Reductase (HMGCR) Cardiovascular Disease Others
    Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.
    Atorvastatin calcium hydrate
  • HY-100001
    SKF-96365 (hydrochloride)
    25+ Cited Publications

    		 TRP Channel CRAC Channel Autophagy CaMK Akt Apoptosis Na+/Ca2+ Exchanger Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    SKF-96365 hydrochloride is a TRPC channel antagonist and store-operated calcium entry (SOCE) inhibitor. SKF-96365 hydrochloride reduces calcium ion influx by inhibiting the activity and expression of TRPC6, STIM1 and Orai1. SKF-96365 hydrochloride inhibits voltage-gated sodium current (cardiac INa/NaV1.5) and slows myocardial conduction. SKF-96365 hydrochloride inhibits phosphorylation/activation of CaMKIIγ and suppresses the downstream AKT signaling pathway. SKF-96365 hydrochloride induces G2/M phase cell cycle arrest, apoptosis and cytoprotective autophagy in colorectal cancer cells. SKF-96365 hydrochloride alleviates allergic rhinitis symptoms by reducing inflammatory cytokine levels. SKF-96365 hydrochloride reduces intracellular calcium overload, inhibits Homer1 expression, prevents nuclear damage and suppresses apoptosis. SKF-96365 hydrochloride inhibits the growth of colorectal cancer xenografts in nude mice . SKF-96365 hydrochloride is applicable to research related to allergic rhinitis, colorectal cancer, Parkinson's disease, persistent spontaneous nociception and hyperalgesia .
    SKF-96365 (hydrochloride)
  • HY-17383
    Levomefolate calcium
    3 Publications Verification

    		 Antifolate Cardiovascular Disease Neurological Disease
    Levomefolate calcium is a synthetic calcium salt of L-5-methyltetrahydrofolate and an orally active and brain-penetrant folate supplement. Levomefolate calcium incorporates into body folate pools to increase plasma and red blood cell folate levels over time. Levomefolate calcium does not significantly increase folate concentrations in breast milk. Levomefolate calcium can be used for the research of neural tube defects and megaloblastic anemia .
    Levomefolate calcium
  • HY-B1371
    Spiperone
    2 Publications Verification

    Spiroperidol

    		 Dopamine Receptor 5-HT Receptor Wnt Neurological Disease
    Spiperone (Spiroperidol) is a potent dopamine D2, serotonin 5-HT1A, and serotonin 5-HT2A antagonist. Spiperone is also a labelled ligand for neuroleptic receptors. Spiperone enhances intracellular calcium level and inhibits the Wnt signaling pathway. Spiperone has the potential for the research of neurology diseases .
    Spiperone
  • HY-P1852
    TIP 39, Tuberoinfundibular Neuropeptide
    1 Publications Verification

    		 Adenylate Cyclase PTHR Neurological Disease
    TIP 39, Tuberoinfundibular Neuropeptide is an endogenous PTH2 receptor agonist and antihypertensive agent. TIP 39, Tuberoinfundibular Neuropeptide selectively activates the PTH2 receptor with no activity on the PTH1 receptor, stimulates cAMP production, activates adenylate cyclase, and elevates intracellular calcium levels via mobilization from intracellular stores. TIP 39, Tuberoinfundibular Neuropeptide is highly conserved in humans, mice, and rats. TIP 39, Tuberoinfundibular Neuropeptide is applicable to research related to nociception and inflammation-induced pain .
    TIP 39, Tuberoinfundibular Neuropeptide
  • HY-14401
    Encaleret

    CLTX-305; JTT-305; MK-5442

    		 CaSR Thyroid Hormone Receptor Metabolic Disease Inflammation/Immunology
    Encaleret (CLTX-305) is an orally active antagonist of the calcium-sensing receptor (CaSR), with an IC50 of 12 nM. Encaleret exerts its effect by inhibiting the excessive activity of functional gain-of-function CaSR variants, and can restore blood calcium levels, promote the secretion of parathyroid hormone, improve magnesium and phosphorus metabolism, and increase urinary calcium excretion. Encaleret can be used in the research of diseases such as osteoporosis and autosomal dominant hypocalcemia type 1 .
    Encaleret
  • HY-W039315
    2,5-Anhydro-D-mannitol, 97%

    		Biochemical Assay Reagents Metabolic Disease
    2,5-Anhydro-D-mannitol, 97% is an antimetabolic fructose analogue. 2,5-Anhydro-D-mannitol, 97% depletes intracellular ATP, reduces oxygen consumption, regulates substrate oxidation, increases phosphomonoester levels, decreases inorganic phosphate levels, and promotes the release of intracellular calcium from intracellular calcium stores via phospholipase C-dependent activity in hepatocytes .
    2,5-Anhydro-D-mannitol, 97%
  • HY-10035
    TTA-P2
    2 Publications Verification

    T-Type calcium channel inhibitor

    		 Calcium Channel Neurological Disease
    TTA-P2 (T-Type calcium channel inhibitor) is a selective, orally active, and BBB-penetrant T-type calcium channel blocker (IC50 = 22 nM). TTA-P2 reduces mechanical hypersensitivity and alleviates acute as well as chronic pain. TTA-P2 significantly reduces firing rates in temporal lobe epilepsy (TLE) neurons to control levels and suppresses synaptically evoked burst firing. TTA-P2 can be studied in research for neurological diseases such as tremor and absence epilepsy < sup>[4] .
    TTA-P2
  • HY-107322
    Barnidipine hydrochloride

    Mepirodipine hydrochloride; YM-09730-5

    		 Calcium Channel Cardiovascular Disease
    Barnidipine (Mepirodipine) hydrochloride is an L-type calcium antagonist (CaA) with high affinity for [ 3H] initrendipine binding sites (Ki = 0.21 nmol/L, has selective action against CaA receptors. Barnidipine hydrochloride is an orally active antihypertensive agent that can reduce the level of platelet-derived growth factor B-chain mRNA and peripheral vascular resistance .
    Barnidipine hydrochloride
  • HY-12363
    U-69593
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    U-69593 is a potent and selective κ1-opioid receptor agonist . U-69593 attenuates addictive agent-induced behavioral sensitization in the rat . U-69593 reduces anxiety and enhances spontaneous alternation memory in mice . U-69593 reduces calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum .
    U-69593
  • HY-12502A
    Efonidipine hydrochloride monoethanolate
    1 Publications Verification

    NZ-105 hydrochloride monoethanolate; (±)-Efonidipine hydrochloride monoethanolate

    		 Calcium Channel SARS-CoV Cardiovascular Disease Neurological Disease Cancer
    Efonidipine (NZ-105) hydrochloride monoethanolate is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC50 values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride monoethanolate inhibits SARS-CoV-2 main protease. Efonidipine hydrochloride monoethanolate modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride monoethanolate reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride monoethanolate improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride monoethanolate can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .
    Efonidipine hydrochloride monoethanolate
  • HY-136460
    Calcium ionophore I

    ETH 1001

    		 Calcium Channel Others
    Calcium ionophore I (ETH 1001) is a selective Ca 2+ ionophore for biological membranes. Calcium ionophore I can be used in Ca2+-selective microelectrodes that can be used for quantitative intracellular measurements of resting Ca2+-activities and of slowly changing Ca2+-levels .
    Calcium ionophore I
  • HY-103302
    SUN B8155

    		CGRP Receptor Endocrinology
    SUN B8155, a non-peptide agonist of calcitonin (CT) receptor, selectively mimics the biological actions of calcitonin. Calcitonin, a 32-amino acid peptide hormone secreted mainly from the thyroid gland, plays an important role in maintaining bone homeostasis .
    SUN B8155
  • HY-P2168
    Demoxytocin

    		Oxytocin Receptor Drug Derivative Metabolic Disease
    Demoxytocin is a heterologous cyclic peptide and an analog of Oxytocin (HY-17571). Demoxytocin affects the permeability of cell membranes and increases calcium ion levels in smooth muscle cells, thereby enhancing the contraction of smooth muscle cells. Demoxytocin also stimulates the contraction of uterine smooth muscle. Demoxytocin possesses the functions of oxytocin. Demoxytocin can be used to study labor stimulation in preterm premature rupture of membranes .
    Demoxytocin
  • HY-B1231
    Heptaminol hydrochloride

    RP-2831 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Heptaminol (RP-2831) hydrochloride is a vasoconstrictor used in the study of hypotension, especially orthostatic hypotension. Heptaminol is also a skin cancer proliferation inhibitor that inhibits immune inflammation induced by the tumor promoting factor 12-O-tetradecanoylphorbol-13-acetate (TPA) in an NO-dependent manner. Heptaminol also acts as a sympathomimetic amine, exerting indirect sympathetic effects. Heptaminol is also an antagonist of catecholamine release and uptake and can increase intracellular free calcium levels .
    Heptaminol hydrochloride
  • HY-N2374
    Eupatorin
    2 Publications Verification

    		 Apoptosis NF-κB MMP Adrenergic Receptor Inflammation/Immunology Cancer
    Eupatorin is an orally active flavonoid with antiproliferative and vasodilatory properties. Eupatorin downregulates the expression levels of NF-κB, MMP9, IL-1β and TNF-α. Eupatorin induces apoptosis, G2/M phase cell cycle arrest, and reactive oxygen species (ROS) production. Eupatorin modulates the activities of muscarinic receptors and β-adrenergic receptors; inhibits sarcoplasmic reticulum calcium release and calcium channels; and activates the NO/sGC/cGMP pathway, indomethacin-sensitive pathway, and potassium channel pathway. Eupatorin exerts cytotoxic effects on cancer cell lines, and is metabolized by CYP1A1 and CYP1 family enzymes to form metabolites with antiproliferative activity. Eupatorin can be used in research related to breast cancer, hypertension, and leukemia .
    Eupatorin
  • HY-B0426A
    Olopatadine hydrochloride

    ALO4943A; KW4679

    		 Histamine Receptor CXCR Infection Neurological Disease Metabolic Disease Inflammation/Immunology
    Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine hydrochloride
  • HY-W145486
    Calcium gluconate

    		Environmental Pollutants Biochemical Assay Reagents Neurological Disease Metabolic Disease Inflammation/Immunology
    Calcium gluconate is an orally effective calcium salt supplement . Calcium gluconate reduces elevated serum potassium, decreased serum calcium, and postoperative myalgia associated with succinylcholine administration. Calcium gluconate restores calcium homeostasis, skeletal integrity, bone mineralization and bone density, and maintains levels of parathyroid hormone, bone resorption markers and osteoclasts. Calcium gluconate reverses LPS (HY-D1056)-induced ERK phosphorylation, inflammatory cytokine release and acute lung injury, alleviates airway inflammatory damage and suppresses immune responses. Calcium gluconate can be used in research related to postoperative myalgia, osteoporosis/osteomalacia and acute lung injury .
    Calcium gluconate
  • HY-112961
    Patiromer

    		JAK Interleukin Related STAT Metabolic Disease
    Patiromer is an orally active, selective and non-absorbable intestinal potassium (K +) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca 2+). Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy .
    Patiromer
  • HY-11095
    NPS 2390

    		mGluR CaSR PI3K Akt mTOR Autophagy Apoptosis Bcl-2 Family Caspase Cardiovascular Disease Neurological Disease
    NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain .
    NPS 2390
  • HY-157088
    C105SR

    		Caspase Apoptosis Cyclophilin Others
    C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC 50 of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model .
    C105SR
  • HY-17522
    Meptyldinocap

    2,4-DNOPC

    		 Fungal ERK JNK p38 MAPK Apoptosis Mitochondrial Metabolism Infection Endocrinology
    Meptyldinocap (2,4-DNOPC) is a fungicide and cytotoxic agent that acts against powdery mildew. Meptyldinocap upregulates the phosphorylation levels of ERK1/2, JNK and p38. Meptyldinocap induces apoptosis and endoplasmic reticulum stress, disrupts calcium homeostasis, inhibits cell proliferation and migration, downregulates the expression of proliferation- and pregnancy-related genes, and triggers mitochondrial dysfunction. Meptyldinocap can be used in studies related to powdery mildew and implantation failure .
    Meptyldinocap
  • HY-12502
    Efonidipine
    1 Publications Verification

    NZ-105; (±)-Efonidipine

    		 Calcium Channel SARS-CoV Cardiovascular Disease Neurological Disease Cancer
    Efonidipine (NZ-105) is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC50 values of 1.8 and 350 nM, respectively. Efonidipine inhibits SARS-CoV-2 main protease. Efonidipine modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine reduces plasma aldosterone levels in vivo. Efonidipine improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .
    Efonidipine
  • HY-P1252
    Parathyroid Hormone (1-34), bovine
    3 Publications Verification

    		 Thyroid Hormone Receptor Metabolic Disease
    Parathyroid Hormone (1-34), bovine is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .
    Parathyroid Hormone (1-34), bovine
  • HY-124042
    K6PC-5
    4 Publications Verification

    		 SphK Filovirus Infection Neurological Disease Inflammation/Immunology
    K6PC-5, a ceramide derivative, is a sphingosine kinase 1(SPHK1) activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research .
    K6PC-5
  • HY-W094517
    Sodium phosphate dibasic heptahydrate

    		Biochemical Assay Reagents Endocrinology
    Sodium phosphate dibasic heptahydrate is an orally active and osmotic laxative, often used as a component of over-the-counter gastrointestinal lavage drugs. Sodium phosphate dibasic heptahydrate draws water into the intestinal lumen, maintains electrical neutrality by retaining cations in the intestinal lumen, and thereby alters fecal volume, consistency and phosphate levels. Sodium phosphate dibasic heptahydrate can be used to generate self-assembled calcium phosphate tubular scaffolds, which support the adhesion, survival and elongation of mesenchymal stem cells. Sodium phosphate dibasic heptahydrate can be applied to research on factitious disorders and related fields .
    Sodium phosphate dibasic heptahydrate
  • HY-W062109
    Olopatadine

    		Histamine Receptor CXCR Inflammation/Immunology
    Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine
  • HY-172458
    Z-3578
    1 Publications Verification

    		 Mas-related G-protein-coupled Receptor (MRGPR) TNF Receptor Inflammation/Immunology
    Z-3578 is an orally active small-molecule antagonist of MrgX2 with potent antipseudoallergic activity, exhibiting a KD value of 729 nM. Z-3578 effectively inhibits mast cell degranulation induced by substance P (SP) and C48/80, suppresses the release of β-hexosaminidase, significantly reduces the release of histamine and TNF-α, and decreases intracellular calcium flux. In a mouse pseudoallergy model, Z-3578 significantly alleviates paw swelling and dye extravasation, and reduces serum histamine levels. Z-3578 can be used for the study of pseudoallergic reactions .
    Z-3578
  • HY-15830
    25,26-Dihydroxyvitamin D3

    25,26-Dihydroxycholecalciferol

    		 VD/VDR Drug Metabolite Drug Derivative Calcium Channel Metabolic Disease
    25,26-Dihydroxyvitamin D3 (25,26-Dihydroxycholecalciferol) is a dihydroxylated derivative and metabolite of Vitamin D3 (HY-15398). 25,26-Dihydroxyvitamin D3 moderately increases serum calcium levels when the initial serum calcium level is low. 25,26-Dihydroxyvitamin D3 promotes intestinal calcium absorption in vitamin D-deficient rats fed a low-calcium diet. 25,26-Dihydroxyvitamin D3 is applicable to research related to osteomalacia .
    25,26-Dihydroxyvitamin D3
  • HY-17504R
    Rosuvastatin Calcium (Standard)
    10+ Cited Publications

    Rosuvastatin hemicalcium (Standard); ZD 4522 calcium (Standard)

    		 Reference Standards HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin (Calcium) (Standard) is the analytical standard of Rosuvastatin (Calcium). This product is intended for research and analytical applications. Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Calcium (Standard)
  • HY-D0110A
    Fura-2 pentapotassium

    		Fluorescent Dye Others
    Fura-2 pentapotassium is a cell-impermeable scaled fluorescent dye that can be used for intracellular calcium imaging. Fura-2 pentapotassium has an emission wavelength of 510 nm and excitation wavelengths of 340 nm or 380 nm and the ratio of 340/380 fluorescence intensity is proportional to the intracellular Ca 2+ level .
    Fura-2 pentapotassium
  • HY-102052
    DCEBIO

    		Potassium Channel Metabolic Disease
    DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia .
    DCEBIO
  • HY-107322A
    Barnidipine

    Mepirodipine; YM-09730-5 Free base

    		 Calcium Channel Cardiovascular Disease
    Barnidipine (Mepirodipine) is an L-type calcium antagonist (CaA) with high affinity for [ 3H] initrendipine binding sites (Ki = 0.21 nmol/L), has selective action against CaA receptors. Barnidipine is an orally effective antihypertensive agent that can reduce the level of platelet-derived growth factor B-chain mRNA and peripheral vascular resistance .
    Barnidipine
  • HY-113040A
    (17R,18S)-Epoxyeicosatetraenoic acid

    17(R),18(S)-EETeTr

    		 Calcium Channel Cardiovascular Disease
    (17R,18S)-Epoxyeicosatetraenoic acid (17 (R),18 (S)-EETeTr) is a physiologically active fatty acid metabolite and also a vasodilator targeting BKα. (17R,18S)-Epoxyeicosatetraenoic acid activates the outward potassium current mediated by BK channels, and this effect is independent of the BKβ1 subunit, intracellular/extracellular calcium levels, and sarcoplasmic reticulum calcium release regulated by RyR3. (17R,18S)-Epoxyeicosatetraenoic acid is produced by the epoxidation of eicosapentaenoic acid mediated by CYP1A1 variants. (17R,18S)-Epoxyeicosatetraenoic acid is applicable to research related to arrhythmia .
    (17R,18S)-Epoxyeicosatetraenoic acid
  • HY-N3741
    Didrovaltrate

    Didrovaltratum

    		 Calcium Channel Reactive Oxygen Species (ROS) Autophagy Inflammation/Immunology Cancer
    Didrovaltrate (Didrovaltratum) is an L-type calcium channel blocker, ROS scavenger, autophagy enhancer, and lipid accumulation inhibitor. Didrovaltrate blocks L-type calcium currents in a concentration-dependent manner, shifts the current-voltage curve upward, modulates steady-state inactivation kinetics, and inhibits the nuclear translocation of glucocorticoid receptors. Didrovaltrate reduces ROS levels, downregulates the expression of muscle atrophy-related genes, enhances autophagy via lipophagy, and decreases Oleic acid-induced lipid accumulation. Didrovaltrate exhibits cytotoxic activity against cancer cells. Didrovaltrate can be used in research related to skeletal muscle atrophy, non-alcoholic fatty liver disease, breast cancer, lung cancer, gastric cancer, and prostate cancer .
    Didrovaltrate
  • HY-17457
    Levalbuterol hemitartrate

    Levosalbutamol hemitartrate

    		 Adrenergic Receptor PI3K Inflammation/Immunology
    Levalbuterol (Levosalbutamol) hemitartrate is a β2-adrenergic receptor agonist and PI3K inhibitor. Levalbuterol hemitartrate inhibits PI3K activity, reduces NF-κB and Rb protein expression, activates the cAMP/PKA pathway, and stimulates cAMP release. Levalbuterol hemitartrate relaxes airway smooth muscle, reduces intracellular calcium levels, and inhibits spasmogen-induced contractions. Levalbuterol hemitartrate can be used for the research of moderate-to-severe asthma .
    Levalbuterol hemitartrate
  • HY-125942
    SKF-96365
    25+ Cited Publications

    		 CRAC Channel TRP Channel CaMK Akt Apoptosis Autophagy Na+/Ca2+ Exchanger Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    SKF-96365 is a TRPC channel antagonist and store-operated calcium entry (SOCE) inhibitor. SKF-96365 reduces calcium ion influx by inhibiting the activity and expression of TRPC6, STIM1 and Orai1. SKF-96365 inhibits voltage-gated sodium current (cardiac INa/NaV1.5) and slows myocardial conduction. SKF-96365 inhibits phosphorylation/activation of CaMKIIγ and suppresses the downstream AKT signaling pathway. SKF-96365 induces G2/M phase cell cycle arrest, apoptosis and cytoprotective autophagy in colorectal cancer cells. SKF-96365 alleviates allergic rhinitis symptoms by reducing inflammatory cytokine levels. SKF-96365 reduces intracellular calcium overload, inhibits Homer1 expression, prevents nuclear damage and suppresses apoptosis. SKF-96365 inhibits the growth of colorectal cancer xenografts in nude mice . SKF-96365 is applicable to research related to allergic rhinitis, colorectal cancer, Parkinson's disease, persistent spontaneous nociception and hyperalgesia .
    SKF-96365
  • HY-N1989
    Bacoside A

    		Na+/K+ ATPase CaMK Apoptosis Cholinesterase (ChE) NO Synthase NF-κB Neurological Disease Cancer
    Bacoside A is an orally active, blood-brain barrier-permeable triterpenoid saponin that modulates the activities of ATPases, AChE, CaMK2A and iNOS. Derived from Bacopa monniera. Bacoside A exerts significant antioxidant, anti-inflammatory and anti-apoptotic effects by maintaining ion balance, scavenging reactive oxygen species, stabilizing cell membranes, and regulating the expression of NF-κB and apoptosis-related proteins. Bacoside A counteracts morphine-induced reductions in Na +/K +-ATPase, Ca 2+-ATPase and Mg 2+-ATPase activities, increases mitochondrial membrane potential, and decreases intracellular reactive oxygen species levels. Bacoside A specifically binds to calcium/calmodulin-dependent protein kinase IIA to trigger endoplasmic reticulum calcium release. Bacoside A exhibits non-apoptotic cytotoxicity against glioblastoma cells while protecting normal nerve cells from stress-induced damage. Bacoside A is applicable to the research of Parkinson's disease and glioblastoma multiforme .
    Bacoside A
  • HY-P5142
    ω-Hexatoxin-Hv1a

    ω-ACTX-Hv1; ω-Atracotoxin-HV1

    		 Insecticide Calcium Channel Apoptosis Necroptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology
    ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a blocks L-type voltage-dependent Ca 2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .
    ω-Hexatoxin-Hv1a
  • HY-W094353
    Calcium acetate hydrate

    		Biochemical Assay Reagents Others
    Calcium acetate hydrate is a type of calcium salt that can be used as a food additive, stabilizer, buffer and isolator. Calcium acetate hydrate can be combined with phosphate in the diet to reduce phosphate levels in the blood .
    Calcium acetate hydrate
  • HY-17383R
    Levomefolate calcium (Standard)

    		Reference Standards Antifolate Cardiovascular Disease Neurological Disease
    Levomefolate calcium (Standard) is the analytical standard of Levomefolate calcium. This product is intended for research and analytical applications. Levomefolate calcium is a synthetic calcium salt of L-5-methyltetrahydrofolate and an orally active and brain-penetrant folate supplement. Levomefolate calcium incorporates into body folate pools to increase plasma and red blood cell folate levels over time. Levomefolate calcium does not significantly increase folate concentrations in breast milk. Levomefolate calcium can be used for the research of neural tube defects and megaloblastic anemia .
    Levomefolate calcium (Standard)
  • HY-W339331
    Flubendiamide

    NNI-0001

    		 Insecticide Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Infection Metabolic Disease
    Flubendiamide (NNI-0001) is an orally active phthalic diamide insecticide that acts by targeting insect ryanodine receptors (RyRs), causing insect muscle dysfunction, paralysis and death. Flubendiamide disrupts molting, metamorphosis and reproductive processes, induces oxidative stress by increasing the levels of ROS/RNS, MDA and 8OHdG and decreasing the levels of SOD, CAT and GST, activates the CncC/Maf apoptosis pathway, impairs calcium homeostasis, promotes adipogenesis, increases triglyceride accumulation, and upregulates the expression of regulatory factors for adipocyte differentiation and adipogenesis .
    Flubendiamide
  • HY-143312E
    (S)-V-0219 hydrochloride

    		GLP Receptor Metabolic Disease
    (S)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 hydrochloride is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice .
    (S)-V-0219 hydrochloride
  • HY-153335
    Enpp-1-IN-16

    		Phosphodiesterase (PDE) Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders .
    Enpp-1-IN-16
  • HY-A0287
    Clomiphene

    Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene

    		 Estrogen Receptor/ERR Metabolic Disease Cancer
    Clomiphene (Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene) is an orally active ovulation-inducing agent. Clomiphene binds to hypothalamic estrogen receptors to elevate FSH levels, and exhibits antiestrogenic or estrogenic properties. Clomiphene can induce erturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes. Clomiphene ameliorates memory impairment in PCOS models. Clomiphene mobilizes cytosolic calcium and reduces viability in prostate cancer cells. Clomiphene can be used for the research of polycystic ovary syndrome (PCOS) and prostate cancer .
    Clomiphene
  • HY-16498
    Tigapotide

    PCK-3145

    		 Apoptosis PTHR Metabolic Disease Cancer
    Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide is applicable for the research of prostate cancer and malignancy-associated hypercalcemia .
    Tigapotide
  • HY-114810
    Prostaglandin F2α serinol amide

    		Prostaglandin Receptor Endocrinology
    Prostaglandin F2α serinol amide is a serinolamide G protein-coupled receptor that increases calcium levels in human non-small cell lung cancer cells. Prostaglandin F2α is also a luteinizing hormone in sheep and may be a nociceptive mediator in the spinal cord .
    Prostaglandin F2α serinol amide
  • HY-120398
    CH5447240

    		PTHR Endocrinology
    CH5447240 is an agonist for parathyroid hormone receptor 1 (PTHR1), that inhibits human PTHR1 with an EC50 of 12 μM. CH5447240 exhibits good metabolic stability in human liver microsomes. CH5447240 increases serum calcium levels in rats. CH5447240 can be used in research about hypoparathyroidism .
    CH5447240

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: